Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimavanserin - ACADIA Pharmaceuticals

Drug Profile

Pimavanserin - ACADIA Pharmaceuticals

Alternative Names: ACP-103; BVF-048; Nuplazid; Pimavanserin tartrate

Latest Information Update: 25 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antidepressants; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Psychotic disorders
  • Phase III Major depressive disorder; Schizophrenia
  • Phase II Agitation
  • Phase I Psychiatric disorders
  • Discontinued Drug-induced akathisia; Drug-induced dyskinesia; Insomnia

Most Recent Events

  • 23 Sep 2019 Safety and efficacy data from a phase II trial in Psychotic disorders (Parkinson's Disease associated with depression) released by Acadia Pharmaceuticals
  • 09 Sep 2019 ACADIA Pharmaceuticals terminates the phase-III HARMONY trial in Psychotic disorders (Dementia associated psychosis) in Bulgaria, Chile, Czech Republic, France, Germany, Italy, Poland, Serbia, Slovakia, Spain, Ukraine, United Kingdom and USA due to early positive results (NCT03325556)
  • 09 Sep 2019 ACADIA Pharmaceuticals plans to meet with the US FDA to discuss the submission of supplemental NDA in 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top